Clinical experience with meloxicam (Movalis®) in nonspecific back pain and radiculopathy
https://doi.org/10.14412/2074-2711-2012-387
Abstract
The authors present their experience in treating 280 patients (115 man and 165 women; mean age 47.1±13.3 years) with acute or chronic nonspecific back pain or radiculopathy. All the patients were given movalis (as intramuscular injections and/or orally in a dose of 15 mg). The majority of patients received myorelaxants; lyrica, milgamma, or other vitamin B preparations were used in radiculopathy. The duration of the treatment in patients with acute, subacute, or chronic pain was 12.1±5.2, 17.1±5.7, and 18.0±7.9 days, respectively. Most (96.4%) patients were observed to have complete regression of pain or its substantial reduction (to 1—2 visual analog scale scores). Movalis therapy showed good tolerability and a low rate (1.8%) of side effects that were transient and required no additional treatment. The positive effect of management in patients with back pain (particular subacute and chronic pain) was largely associated with the use of the elements of rational psychotherapy and therapeutic exercises.
References
1. <div><p>Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. В кн.: Болезни нервной системы. Рук-во для врачей. Под ред. Н.Н. Яхно. Т. 2. М.: Медицина; 2005;306—31.</p><p>Подчуфарова Е.В., Яхно Н.Н. Боль в спине. М.: ГЭОТАР-Медиа, 2010; 368 с.</p><p>Van Tulder M., Becker A., Bekkering T. et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006;15(Suppl. 2):S.169— S.191.</p><p>Airaksinen O., Brox J. I., Cedraschi C. et al. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;15(Suppl. 2):S192—S300.</p><p>Chou R., Huffman L.H. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Int Med 2007;147:492—504.</p><p>Chou R., Atlas S.J., Stanos S.P. et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine 2009;34:1078—93.</p><p>Hayden J.A., van Tulder M.W., Malmivaara A. et al. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005;3:CD000335.</p><p>Colberg K., Hettich M., Sigmund R. et al. ЛИТЕРАТУРА The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Curr Med Res Opin 1996;13:363—77.</p><p>Шостак Н.А., Аксенова А.В., Шеметов Д.А. и др. Опыт применения Мовалиса при синдроме болей в нижней части спины (LBP). Тер арх 1999;11:50—2.</p><p>Dreiser R.L., Parc J.M., Velicitat P. et al. Oral meloxicam is effective in acute sciatica: two randomized, double-blind trials versus placebo or diclofenac. Inflam Res 2001;50(Suppl. 1):17—23.</p><p>Алексеев В.В., Подчуфарова Е.В. Применение мелоксикама (мовалиса) в лечении люмбоишиалгического синдрома. Боль 2004;4:49—53.</p><p>Гузева В.И., Гайгалас Л.М., Разумовский М.А. Мовалис в лечении острых дорсопатий. Журн неврол психиатр 2004;5:58—9.</p><p>Филатова Е.Г., Кондриков А.В., Истомина О.И. Эффективность и переносимость лечения боли в нижней части спины с использованием инъекционной и таблетированной форм Мовалиса (мелоксикама). Фарматека 2008;3:23—5.</p><p>Герасимова О.Н., Парфенов В.А. Лечение острой неспецифической боли в спине в амбулаторной практике. Неврол нейроп сихиатр психосом 2009;3—4:40—6.</p><p>Герасимова О.Н., Парфенов В.А. Ведение пациентов с болью в спине в амбулаторной практике. Неврол нейропсихиатр психосом 2010;4:65—71.</p><p>Dworkin R.H., O'Connor A.B., Backonja M. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237—51.</p><p>Atttal N., Cruccu G., Baron R. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113—e88.</p><p>Подчуфарова Е.В. Дискогенная пояснично-крестцовая радикулопатия. Неврол нейропсихиатр психосом 2010;3:32—9.</p><p>Герасимова О.Н., Парфенов В.А. Фармакоэкономический анализ применения мовалиса при болях в спине. Неврол нейропсихиатр психосом 2011;4:27—32.</p><p>Singh G., Lanes S., Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004;117:100—6.</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Rheumatology (Oxford) 1999;38:793—8.</p></div><br />
Review
For citations:
Gerasimova O.N., Parfenov V.A. Clinical experience with meloxicam (Movalis®) in nonspecific back pain and radiculopathy. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):68-73. (In Russ.) https://doi.org/10.14412/2074-2711-2012-387
Views: 1635
Email this article 